Literature DB >> 29413360

A sixteen-week three-armed, randomized, controlled trial investigating clinical and biochemical effects of targeted alterations in dietary linoleic acid and n-3 EPA+DHA in adults with episodic migraine: Study protocol.

John Douglas Mann1, Keturah R Faurot2, Beth MacIntosh3, Olafur S Palsson4, Chirayath M Suchindran5, Susan Ann Gaylord6, Chanee Lynch7, Angela Johnston8, Kristen Maiden9, David A Barrow10, Joseph R Hibbeln11, Christopher E Ramsden12.   

Abstract

Migraine is a prevalent neurological disorder, affecting over 16% of adult women and 7% of adult men in the U.S., causing significant pain, disability, and medical expense, with incomplete benefits from conventional medical management. Migraine, as a chronic pain syndrome, provides a practical model for investigating the impact of dietary modifications in omega-3 (n-3) and omega-6 (n-6) fatty acids. This paper reports the protocol of a trial to assess whether targeted dietary modifications designed to increase n-3 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), with or without concurrent reduction in n-6 linoleic acid (LA), will alter nociceptive lipid mediators and mediate decreases in frequency and severity of migraine. This prospective, randomized, controlled trial in 153 male and female adult subjects, ages 18-99, with diagnosed and actively managed episodic migraine tests the efficacy, safety, and biochemical effects of targeted, controlled alterations in dietary omega-3 and omega-6 fatty acids. Participants are masked to diet hypotheses and all assessors are masked to treatment assignment. Following a four-week baseline period, participants with migraine headache frequency of 5-20 per month are randomized to one of three intensive dietary regimens for 16 additional weeks followed by a less intensive observation period. Dietary intervention arms include: 1) increased n-3 EPA+DHA with low n-6 linoleic acid (H3 L6); 2) increased n-3 EPA+DHA with usual US dietary intake of n-6 linoleic acid (H3 H6); and 3) usual US dietary content of n-3 and n-6 fatty acids (L3 H6). During the actual intervention, subjects receive content-specific study oils and foods sufficient for two meals and two snacks per day, as well as dietary counseling. Biochemical and clinical outcome measures are performed at intervals throughout this period. This randomized controlled trial is designed to determine whether targeted alterations in dietary n-3 and n-6 fatty acids can alter nociceptive lipid mediators in a manner that decreases headache pain and enhances quality of life and function in adults with frequent migraines. TRIAL REGISTRATION: NCT02012790.
Copyright © 2017. Published by Elsevier Ltd.

Entities:  

Keywords:  Diet; Headache; Linoleic acid; Lipid mediator; Migraine; Omega-3; Omega-6; Oxylipin, pain; RCT

Mesh:

Substances:

Year:  2017        PMID: 29413360      PMCID: PMC6269096          DOI: 10.1016/j.plefa.2017.11.002

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  41 in total

1.  Reliability and validity of a diabetes quality-of-life measure for the diabetes control and complications trial (DCCT). The DCCT Research Group.

Authors: 
Journal:  Diabetes Care       Date:  1988-10       Impact factor: 19.112

2.  Heat generates oxidized linoleic acid metabolites that activate TRPV1 and produce pain in rodents.

Authors:  Amol M Patwardhan; Armen N Akopian; Nikita B Ruparel; Anibal Diogenes; Susan T Weintraub; Charis Uhlson; Robert C Murphy; Kenneth M Hargreaves
Journal:  J Clin Invest       Date:  2010-04-26       Impact factor: 14.808

Review 3.  Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability.

Authors:  W F Stewart; R B Lipton; A J Dowson; J Sawyer
Journal:  Neurology       Date:  2001       Impact factor: 9.910

Review 4.  The global burden of headache: a documentation of headache prevalence and disability worldwide.

Authors:  Lj Stovner; K Hagen; R Jensen; Z Katsarava; Rb Lipton; Ai Scher; Tj Steiner; J-A Zwart
Journal:  Cephalalgia       Date:  2007-03       Impact factor: 6.292

5.  Dietary linoleic acid and polyunsaturated fatty acids in rat brain and other organs. Minimal requirements of linoleic acid.

Authors:  J M Bourre; M Piciotti; O Dumont; G Pascal; G Durand
Journal:  Lipids       Date:  1990-08       Impact factor: 1.880

Review 6.  The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies.

Authors:  Rebecca C Burch; Stephen Loder; Elizabeth Loder; Todd A Smitherman
Journal:  Headache       Date:  2015-01       Impact factor: 5.887

7.  Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids.

Authors:  Christophe Morisseau; Bora Inceoglu; Kara Schmelzer; Hsing-Ju Tsai; Steven L Jinks; Christine M Hegedus; Bruce D Hammock
Journal:  J Lipid Res       Date:  2010-07-27       Impact factor: 5.922

8.  Analgesic use: a predictor of chronic pain and medication overuse headache: the Head-HUNT Study.

Authors:  J-A Zwart; G Dyb; K Hagen; S Svebak; J Holmen
Journal:  Neurology       Date:  2003-07-22       Impact factor: 9.910

9.  Activation of TRPV1 in the spinal cord by oxidized linoleic acid metabolites contributes to inflammatory hyperalgesia.

Authors:  Amol M Patwardhan; Phoebe E Scotland; Armen N Akopian; Kenneth M Hargreaves
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-20       Impact factor: 11.205

Review 10.  The omega-3 index: from biomarker to risk marker to risk factor.

Authors:  William S Harris
Journal:  Curr Atheroscler Rep       Date:  2009-11       Impact factor: 5.113

View more
  8 in total

1.  The need for precision nutrition, genetic variation and resolution in Covid-19 patients.

Authors:  Artemis P Simopoulos; Charles N Serhan; Richard P Bazinet
Journal:  Mol Aspects Med       Date:  2021-01-28

Review 2.  Prospects on the Use of Schizochytrium sp. to Develop Oral Vaccines.

Authors:  Abel Ramos-Vega; Sergio Rosales-Mendoza; Bernardo Bañuelos-Hernández; Carlos Angulo
Journal:  Front Microbiol       Date:  2018-10-25       Impact factor: 5.640

3.  Migraine day frequency in migraine prevention: longitudinal modelling approaches.

Authors:  Gian Luca Di Tanna; Joshua K Porter; Richard B Lipton; Alan Brennan; Stephen Palmer; Anthony J Hatswell; Sandhya Sapra; Guillermo Villa
Journal:  BMC Med Res Methodol       Date:  2019-01-23       Impact factor: 4.615

4.  Leukocyte inflammatory phenotype and function in migraine patients compared with matched non-migraine volunteers: a pilot study.

Authors:  Hongtao Li; Qiang Fu; Kamaira Philips; Yufei Sun; Keturah R Faurot; Susan A Gaylord; John Douglas Mann
Journal:  BMC Neurol       Date:  2022-07-27       Impact factor: 2.903

5.  Methodology for altering omega-3 EPA+DHA and omega-6 linoleic acid as controlled variables in a dietary trial.

Authors:  Beth A MacIntosh; Christopher E Ramsden; Gilson Honvoh; Keturah R Faurot; Olafur S Palsson; Angela D Johnston; Chanee Lynch; Paula Anderson; Daria Igudesman; Daisy Zamora; Mark Horowitz; Susan Gaylord; John D Mann
Journal:  Clin Nutr       Date:  2021-05-12       Impact factor: 7.643

6.  Adjunctive dietary intervention for bipolar disorder: a randomized, controlled, parallel-group, modified double-blinded trial of a high n-3 plus low n-6 diet.

Authors:  Erika F H Saunders; Dahlia Mukherjee; Tiffany Myers; Emily Wasserman; Ahmad Hameed; Venkatesh Bassappa Krishnamurthy; Beth MacIntosh; Anthony Domenichiello; Christopher E Ramsden; Ming Wang
Journal:  Bipolar Disord       Date:  2021-08-02       Impact factor: 5.345

7.  Identifying oxidized lipid mediators as prognostic biomarkers of chronic posttraumatic headache.

Authors:  Anthony F Domenichiello; Jennifer R Jensen; Daisy Zamora; Mark Horowitz; Zhi-Xin Yuan; Keturah Faurot; J Douglas Mann; Andrew J Mannes; Christopher E Ramsden
Journal:  Pain       Date:  2020-12       Impact factor: 7.926

8.  Comparing prospective headache diary and retrospective four-week headache questionnaire over 20 weeks: Secondary data analysis from a randomized controlled trial.

Authors:  Vanessa E Miller; Keturah R Faurot; Olafur S Palssson; Beth A MacIntosh; Chirayath Suchindran; Gilson Honvoh; Susan Gaylord; Christopher E Ramsden; J Douglas Mann
Journal:  Cephalalgia       Date:  2020-08-16       Impact factor: 6.075

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.